Last Price
5.22
Today's Change
-0.053 (1.00%)
Day's Change
5.19 - 5.49
Trading Volume
9,701
Market Cap
6 Million
Shares Outstanding
1 Million
Avg Volume
15,210
Avg Price (50 Days)
6.39
Avg Price (200 Days)
8.78
PE Ratio
-0.02
EPS
-302.63
Earnings Announcement
13-Mar-2025
Previous Close
5.28
Open
5.38
Day's Range
5.1973 - 5.49
Year Range
5.197 - 20.275
Trading Volume
9,712
1 Day Change
-1.00%
5 Day Change
-9.41%
1 Month Change
-6.16%
3 Month Change
-28.30%
6 Month Change
-44.27%
Ytd Change
-18.33%
1 Year Change
-61.54%
3 Year Change
-99.79%
5 Year Change
-99.89%
10 Year Change
-99.96%
Max Change
-99.94%
No result.
Sector: Healthcare - Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Description:
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.